Competition for additional information. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong ...
Q2 FY2026 — expected 2026-08-23
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-24 | 2025-12-31 | 0001193125-26-065197 | EDGAR | 88K words |
| 2025-02-25 | 2024-12-31 | 0000950170-25-026068 | EDGAR | — |
| 2024-02-27 | 2023-12-31 | 0000950170-24-021074 | EDGAR | — |
| 2023-03-09 | 2022-12-31 | 0000950170-23-006841 | EDGAR | — |
| 2022-03-03 | 2021-12-31 | 0000950170-22-002727 | EDGAR | — |
| 2021-03-04 | 2020-12-31 | 0001564590-21-010715 | EDGAR | — |
| 2020-03-05 | 2019-12-31 | 0001564590-20-008951 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-07-30 | 2026-06-30 | 0001193125-26-326098 | EDGAR | — |
| 2025-10-29 | 2025-09-30 | 0001193125-25-254633 | EDGAR | 56K words |
| 2025-07-29 | 2025-06-30 | 0000950170-25-099407 | EDGAR | — |
| 2025-05-01 | 2025-03-31 | 0000950170-25-061442 | EDGAR | — |
| 2024-11-13 | 2024-09-30 | 0000950170-24-125931 | EDGAR | — |
| 2024-07-31 | 2024-06-30 | 0000950170-24-088238 | EDGAR | — |
| 2024-05-13 | 2024-03-31 | 0000950170-24-058193 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0000950170-23-059755 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0000950170-23-037579 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0000950170-23-021960 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0000950170-22-022913 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016644 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-10 | 0001193125-26-341385 | EDGAR | — |
| 2026-02-24 | 0001193125-26-065190 | EDGAR | 2K words |
| 2026-01-12 | 0001193125-26-009845 | EDGAR | — |
| 2025-12-11 | 0001193125-25-314728 | EDGAR | — |
| 2025-12-08 | 0001193125-25-310509 | EDGAR | — |
| 2025-10-29 | 0001193125-25-254619 | EDGAR | — |
| 2025-08-28 | 0001193125-25-190746 | EDGAR | — |
| 2025-07-29 | 0000950170-25-099404 | EDGAR | — |
| 2025-06-27 | 0001193125-25-151276 | EDGAR | — |
| 2025-05-01 | 0000950170-25-061439 | EDGAR | — |
132 total filings indexed. 103 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001680581 |
| Ticker | FULC |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.fulcrumtx.com |
| Listed | 2019-07-18 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/FULC (~200 tokens, structured JSON with cryptographic provenance)